Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer

By  

Current Cancer Drug Targets, Vol. 18, Iss. 8, 2018-10 ,pp. : 773-791

Bentham Science Publishers

Access to resources Recommend Favorite

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib

By Reckamp Karen L.   Giaccone Giuseppe   Camidge D. Ross   Gadgeel Shirish M.   Khuri Fadlo R.   Engelman Jeff A.   Koczywas Marianna   Rajan Arun   Campbell Alicyn K.   Gernhardt Diana   Ruiz-Garcia Ana   Letrent Stephen   Liang Jane   Taylor Ian   O'Connell Joseph P.   Jänne Pasi A.  

Cancer, Vol. 120, Iss. 8, 2014-04 ,pp. : 1145-1154

Blackwell Publishing

Access to resources Recommend Favorite

Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinib

By  

Cancer, Vol. 120, Iss. 24, 2014-12 ,pp. : 3896-3901

Blackwell Publishing

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer

By  

Current Pharmaceutical Design, Vol. 19, Iss. 5, 2013-02 ,pp. : 818-832

Bentham Science Publishers

Access to resources Recommend Favorite

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

By Naidoo Jarushka   Sima Camelia S.   Rodriguez Katherine   Busby Natalie   Nafa Khedoudja   Ladanyi Marc   Riely Gregory J.   Kris Mark G.   Arcila Maria E.   Yu Helena A.  

Cancer, Vol. 121, Iss. 18, 2015-09 ,pp. : 3212-3220

Blackwell Publishing

Access to resources Recommend Favorite